HLA-C and neoplasm: Conventional ACT approaches, such as tumor-infiltrating lymphocyte (TIL) therapy and T-cell receptor-engineered T-cell (TCR-T) therapy, which recognize only MHC-delivered antigens, may be limited by down-regulation or mutation of MHC molecules of the tumor cells, thus evading immune surveillance, which has certain limitations in the clinic (9, 10).